Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Marcelo V Negrão ,Minh Truong ,Collin M Blakely ,Qi Wang ,Turja Chakrabarti ,Jürgen Wolf ,Mingjia Li ,Gabriele Minuti ,Joao Alessi ,Yun Qing ,Jacqueline V Aredo ,Alissa J Cooper ,Christine M Bestvina ,Shu-Chi Tseng ,Matthias Scheffler ,So Yeon Kim ,Neal S Akhave ,Mark M Awad ,J Kevin Hicks ,Rebecca S Heist ,Petros Christopoulos ,Jing Wang ,Giannis Mountzios ,Subba R Digumarthy ,Giorgio Vittorio Scagliotti ,Leylah Drusbosky ,Dwight H Owen ,Sarah B Goldberg ,Fabrice Barlési ,Don L Gibbons ,Ara A Vaporciyan ,Jhanelle E Gray ,Lorenza Landi ,Waree Rinsurongkawong ,Teng Zhou ,Blerina Resuli ,Jacobi Hines ,David S Hong ,John V Heymach ,Michael Dennis ,Heather A Wakelee ,Catherine A Shu ,Pradnya D Patil ,John Lee ,Lukas Delasos ,George R Blumenschein ,Haniel A Araújo ,Amy L Cummings ,Mizuki Nishino ,Sandip Pravin Patel ,Jonathan W Riess ,Federico Cappuzzo ,Jianjun Zhang ,Richard Lee ,Funda Meric‐Bernstam ,Mihaela Aldea ,Paolo Bironzo ,Kristen A Marrone ,Ying Ni ,Susan C Scott ,Biagio Ricciuti ,Vadeerat Rinsurongkawong ,Marina Chiara Garassino ,Giuseppe Lamberti ,Albrecht Stenzinger ,Ferdinandos Skoulidis

doi:10.1158/2159-8290.cd-22-1420

Abstract

In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501.

Full Text